Introduction
Healthcare antitrust is more nuanced than "new administration, less enforcement" suggests. The current FTC is more permissive toward large M&A and readier to settle for divestitures, yet healthcare has produced its highest-profile courtroom win, its heaviest remedies, and conduct cases aimed at drug and hospital pricing. For bankers, enforcement drives timeline, structure, and deal certainty.
Current Enforcement Posture
Three areas absorb most of the FTC's healthcare merger attention.
Device pipelines, not just device markets. The agency's biggest healthcare win came in a market with no approved product. The FTC sued in August 2025 to block Edwards Lifesciences' $945 million acquisition of JenaValve, alleging the two were the only companies running US clinical trials for transcatheter valves treating aortic regurgitation (TAVR-AR), a field Edwards had already consolidated by buying JC Medical. A DC federal court granted a preliminary injunction on January 9, 2026, and Edwards walked away. In March, Alcon dropped its LENSAR acquisition, worth about $356 million upfront, after FTC staff found it would combine the two most significant suppliers of femtosecond cataract lasers; the parties abandoned it rather than face the FTC in court. Neither was a large-market case, so both matter beyond their niches.
- Innovation Market Theory
An antitrust theory under which the FTC challenges a deal for eliminating a future competitor rather than lessening competition in an existing product market. It covers buying a clinical-stage rival or, as in Edwards/JenaValve, combining two pre-approval products, so a target with no revenue can still draw a challenge.
Private equity roll-ups, reframed. The FTC has filed no new serial-acquisition complaint since its 2023 case against U.S. Anesthesia Partners and Welsh Carson. Welsh Carson, a minority holder, was dismissed from the federal case in 2024 and accepted a 2025 consent order freezing its stake; the FTC reached an agreement in principle with USAP in April 2026 on undisclosed terms. Leadership has signalled private equity ownership alone is not a theory of harm, yet platforms still face structural remedies: sponsor-backed Sevita cleared its $835 million purchase of BrightSpring's community living business only by divesting 128 intermediate care facilities. When modelling how sponsors build and exit healthcare platforms, treat divestiture risk, not challenge risk, as the base case.
Healthcare labor and staffing infrastructure. Aya Healthcare let its roughly $615 million deal for Cross Country Healthcare lapse in December 2025, a year after signing. The FTC never sued, but its Bureau of Competition said the merger would have eliminated head-to-head competition between two of the largest suppliers of travel-nurse management services to hospitals. Review length alone can kill a labor-market deal.
Remedies, Not Blocks, Define Most Outcomes
The 2026 pattern is settlement with structure attached. Ascension Health's $3.9 billion AmSurg acquisition cleared in June 2026 on condition that Ascension divest seven ambulatory surgery centers in five metro areas, and the FTC approved the final consent order in August. That order and Sevita's carry ten-year advance-notice obligations on future acquisitions in the affected areas, so a buyer accepting a remedy runs its tuck-in strategy under supervision for a decade, which weighs on its exit multiple.
Conduct Cases: PBM Rebates and Hospital Contracts
Some of the most consequential actions involve no merger. The FTC's insulin-rebate case alleged the three largest pharmacy benefit managers favored high-list-price insulins to earn bigger rebates while patient cost-sharing tracked list price. Express Scripts settled in February 2026, agreeing to offer plan sponsors an option basing member costs on net price and delinking manufacturer compensation from list prices. Caremark settled on similar terms in July; Optum Rx reached a proposed settlement in June. The orders shrink the rebate layer of the gross-to-net waterfall and push PBMs toward fee-based revenue.
Hospital contracting is the other front. The FTC launched a cross-bureau Healthcare Task Force on March 20, 2026 to tie merger review to conduct investigations, and the DOJ sued OhioHealth and NewYork-Presbyterian over anti-steering and anti-tiering terms that keep insurers from steering patients to cheaper providers. OhioHealth settled in June by agreeing to drop those clauses; NewYork-Presbyterian is fighting its case. A target's payer contracts are now an antitrust diligence item, not just a revenue one.
State-Level Enforcement Expansion
Roughly a dozen states now run healthcare-specific transaction notice or approval regimes, including California, Massachusetts, New York, Oregon, and Washington, and more bills appear every session. Some reach only hospital mergers; others reach physician practices, and several capture private equity, management services organizations, and real estate structures. Notice periods run from 60 days in Massachusetts and Washington to 90 days in California and 180 days under Maine's law effective January 2027. The patchwork hits multi-state roll-ups hardest, since one add-on can trigger notices in several states.
Antitrust analysis belongs at the front of a transaction: pipeline theories, remedies, conduct cases, and state review all shape deal certainty, timeline, and the value a buyer keeps.
The next article examines healthcare capital markets in 2026 and the biotech IPO market.
